ReviewAllergy, asthma & immunology research2015
Specific immunotherapy in atopic dermatitis.
Review in Allergy, asthma & immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Specific allergen immunotherapy for the treatment of atopic eczema.The Cochrane database of systematic reviews · 2016Pooled it
- The Effectiveness of Allergen Immunotherapy in Adult Patients with Atopic Dermatitis Allergic to House Dust Mites.Medicina (Kaunas, Lithuania) · 2022Trial
- Advancements in Allergen Immunotherapy for the Treatment of Atopic Dermatitis.International journal of molecular sciences · 2024Review
- Attenuation of allergen-specific immunotherapy for atopic dermatitis by ectopic colonization of Brevundimonas vesicularis in the intestine.Cell reports. Medicine · 2023Article
- Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites.Postepy dermatologii i alergologii · 2023Article
- How an Immune-Factor-Based Formulation of Micro-Immunotherapy Could Interfere with the Physiological Processes Involved in the Atopic March.International journal of molecular sciences · 2023Review
- House Dust Mite Precision Allergy Molecular Diagnosis (PAMD@) in the Th2-prone Atopic Dermatitis Endotype.Life (Basel, Switzerland) · 2021Article
- Mite allergy and atopic dermatitis: Is there a clear link? (Review).Experimental and therapeutic medicine · 2020Review
- Dendritic Cell-Mediated Th2 Immunity and Immune Disorders.International journal of molecular sciences · 2019Review
- Immunotherapy of house dust mite allergy.Human vaccines & immunotherapeutics · 2017Review
- Oral administration of lactobacilli isolated fromExperimental and therapeutic medicine · 2017Article
- Clinical Diversity of Atopic Dermatitis: A Review of 5,000 Patients at a Single Institute.Allergy, asthma & immunology research · 2017Article
- Different Responses in Induction of Allergen Specific Immunoglobulin G4 and IgE-Blocking Factors for Three Mite Subcutaneous Immunotherapy Products.Yonsei medical journal · 2016Article
- Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis.Yonsei medical journal · 2016Article
- TIM-3 is not essential for development of airway inflammation induced by house dust mite antigens.Allergology international : official journal of the Japanese Society of Allergology · 2016Article
- Short-, Intermediate-, and Long-Term Changes in Basophil Reactivity Induced by Venom Immunotherapy.Allergy, asthma & immunology research · 2016Article
- Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: Long-Term Changes of Clinical Severity and Laboratory Parameters.Allergy, asthma & immunology research · 2016Article
- Allergen Immunotherapy: Past, Present, and Future.Allergy, asthma & immunology research · 2016Review
- Induction of Bronchial Tolerance After 1 Cycle of Monophosphoryl-A-Adjuvanted Specific Immunotherapy in Children With Grass Pollen Allergies.Allergy, asthma & immunology research · 2016Article
- Consensus Conference on Clinical Management of pediatric Atopic Dermatitis.Italian journal of pediatrics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen specific immunotherapy (SIT) using house dust mite (HDM) extracts has been performed mainly with patients of asthma and allergic rhinitis. In the meanwhile, there has been a long debate on the efficacy of SIT in atopic dermatitis (AD) with only a few double-blind placebo-controlled trials. However, several randomized controlled trials of SIT in AD revealed significant improvement of clinical symptoms and also, positive result was shown by a following meta-analysis study of these trials. In order to predict and evaluate the treatment outcome, finding a biomarker that can predict treatment responses and treatment end-points is critical but it is very challenging at the same time due to the complexity of causes and mechanisms of AD. Other considerations including standardization of the easiest and safest treatment protocol and optimizing the treatment preparations should be studied as well. This review summarizes the basics of SIT in AD including the brief mechanisms, treatment methods and schedules, and also highlights the clinical efficacy of SIT in AD along with mild, controllable adverse reactions. Immunologic effects and studies of various biomarkers are also introduced and finally, future considerations with upcoming studies on SIT were discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.